334 related articles for article (PubMed ID: 31202128)
21. DNA binding and evaluation of anticancer activity in vitro and in vivo of iridium(III) polypyridyl complexes.
Zhang Y; Zhou Y; Zhang H; Tian L; Hao J; Yuan Y; Li W; Liu Y
J Inorg Biochem; 2021 Nov; 224():111580. PubMed ID: 34438219
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, characterization, anticancer efficacy evaluation of ruthenium(II) and iridium(III) polypyridyl complexes toward A549 cells.
Liang L; Yang Y; Liu H; Yuan F; Yuan Y; Li W; Huang C; Chen J; Liu Y
J Biol Inorg Chem; 2023 Jun; 28(4):421-437. PubMed ID: 37097484
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, biological evaluation of novel iridium(III) complexes targeting mitochondria toward melanoma B16 cells.
Yuan Y; Zhang Y; Chen J; Huang C; Liu H; Li W; Liang L; Wang Y; Liu Y
Eur J Med Chem; 2023 Feb; 247():115046. PubMed ID: 36577214
[TBL] [Abstract][Full Text] [Related]
24. Studies of anticancer activity in vivo and in vitro behaviors of liposomes encapsulated iridium(III) complex.
Gu Y; Wen H; Zhang Y; Bai L; Zhou Y; Zhang H; Tian L; Hao J; Liu Y
J Biol Inorg Chem; 2021 Feb; 26(1):109-122. PubMed ID: 33475857
[TBL] [Abstract][Full Text] [Related]
25. Mitochondria-targeted phosphorescent cyclometalated iridium(III) complexes: synthesis, characterization, and anticancer properties.
Li Y; Liu B; Xu CX; He L; Wan YC; Ji LN; Mao ZW
J Biol Inorg Chem; 2020 Jun; 25(4):597-607. PubMed ID: 32232583
[TBL] [Abstract][Full Text] [Related]
26. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
27. In Vitro and In Vivo of Triphenylamine-Appended Fluorescent Half-Sandwich Iridium(III) Thiosemicarbazones Antitumor Complexes.
Shao M; Yao M; Liu X; Gao C; Liu W; Guo J; Zong J; Sun X; Liu Z
Inorg Chem; 2021 Nov; 60(22):17063-17073. PubMed ID: 34709784
[TBL] [Abstract][Full Text] [Related]
28. Alkyl chain-modified cyclometalated iridium complexes as tunable anticancer and imaging agents.
Laha P; De U; Chandra F; Dehury N; Khullar S; Kim HS; Patra S
Dalton Trans; 2018 Nov; 47(44):15873-15881. PubMed ID: 30358775
[TBL] [Abstract][Full Text] [Related]
29. Enhanced in vitro cytotoxicity and antitumor activity in vivo of iridium(III) complexes liposomes targeting endoplasmic reticulum and mitochondria.
Li W; Wu X; Liu H; Shi C; Yuan Y; Bai L; Liao X; Zhang Y; Liu Y
J Inorg Biochem; 2022 Aug; 233():111868. PubMed ID: 35636300
[TBL] [Abstract][Full Text] [Related]
30. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes.
Ludwig G; Mojić M; Bulatović M; Mijatović S; Maksimović-Ivanić D; Steinborn D; Kaluđerović GN
Anticancer Agents Med Chem; 2016; 16(11):1455-1460. PubMed ID: 26510901
[TBL] [Abstract][Full Text] [Related]
31. Iridium (III) complexes induce cervical carcinoma apoptosis via disturbing cellular redox homeostasis disorder and inhibiting PI3K/AKT/mTOR pathway.
Hao J; Liu H; Wang J; Wang X; Huang C; Liang L; Chen J; Wang Y; Liu Y
J Inorg Biochem; 2022 Oct; 235():111946. PubMed ID: 35932758
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and antitumor mechanism investigation of iridium(III) complexes conjugated with ibuprofen.
Chen SQ; Lu XY; Zhu LY; Zhu H; Li RT; Ye RR
J Inorg Biochem; 2024 Aug; 257():112596. PubMed ID: 38759264
[TBL] [Abstract][Full Text] [Related]
33. Antitumor Effects of Ir(III)-2
Panchangam RL; Rao RN; Balamurali MM; Hingamire TB; Shanmugam D; Manickam V; Chanda K
Inorg Chem; 2021 Dec; 60(23):17593-17607. PubMed ID: 34767343
[TBL] [Abstract][Full Text] [Related]
34. Mitochondria-targeted cyclometalated iridium (III) complexes: Dual induction of A549 cells apoptosis and autophagy.
Chen L; Tang H; Chen W; Wang J; Zhang S; Gao J; Chen Y; Zhu X; Huang Z; Chen J
J Inorg Biochem; 2023 Dec; 249():112397. PubMed ID: 37844533
[TBL] [Abstract][Full Text] [Related]
35. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
36. Exploring anticancer efficiency of mitochondria-targeted cyclometalated iridium(III) complexes.
Gu Y; Wen H; Bai L; Zhou Y; Zhang H; Tian L; Zhang Y; Hao J; Liu Y
J Inorg Biochem; 2020 Nov; 212():111215. PubMed ID: 32919250
[TBL] [Abstract][Full Text] [Related]
37. Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands.
Ludwig G; Ranđelović I; Maksimović-Ivanić D; Mijatović S; Bulatović MZ; Miljković D; Korb M; Lang H; Steinborn D; Kaluđerović GN
ChemMedChem; 2014 Jul; 9(7):1586-93. PubMed ID: 24470190
[TBL] [Abstract][Full Text] [Related]
38. Triphenylamine-appended cyclometallated iridium(III) complexes: Preparation, photophysical properties and application in biology/luminescence imaging.
Liu X; Hao H; Ge X; He X; Liu Y; Wang Y; Wang H; Shao M; Jing Z; Tian L; Liu Z
J Inorg Biochem; 2019 Oct; 199():110757. PubMed ID: 31445461
[TBL] [Abstract][Full Text] [Related]
39. Iridium(III) complexes inhibit the proliferation and migration of BEL-7402 cells through the PI3K/AKT/mTOR signaling pathway.
Chen J; Liu H; Chen Y; Hu H; Huang C; Wang Y; Liang L; Liu Y
J Inorg Biochem; 2023 Apr; 241():112145. PubMed ID: 36709684
[TBL] [Abstract][Full Text] [Related]
40. Ferrocene-Appended Iridium(III) Complexes: Configuration Regulation, Anticancer Application, and Mechanism Research.
Ge X; Chen S; Liu X; Wang Q; Gao L; Zhao C; Zhang L; Shao M; Yuan XA; Tian L; Liu Z
Inorg Chem; 2019 Oct; 58(20):14175-14184. PubMed ID: 31559820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
